Pioneering Off‑the‑Shelf, Allogeneic T‑Cell Immunotherapies
Mission to transform the lives of patients with serious medical conditions through pioneering science, teamwork and a commitment to excellence
About UsRobust T‑Cell Immunotherapy Pipeline
Four Strategic Priorities
- Tab-cel® (tabelecleucel)
- ATA188
- ATA2271 & ATA3271
- ATA3219
Patient Stories
“I learned how to cultivate wonder about life’s simple moments because I didn’t know how many moments I had left.”
Doug
Doug
“Don’t give up. That’s the main thing.”
Ayden
Ayden
“I have always been very aware of the preciousness of life and that it is something we cannot take for granted.”
Jessica
Jessica
“I am who I am because of my disability. People read my story and say, ‘You are a role model to me.’ Hearing that from others is what drives me forward.”
Ola
Ola
Patient Stories
“I learned how to cultivate wonder about life’s simple moments because I didn’t know how many moments I had left.”Doug
Patient Stories
“Don’t give up. That’s the main thing.”Ayden
Patient Stories
“I have always been very aware of the preciousness of life and that it is something we cannot take for granted.”Jessica
Patient Stories
“I am who I am because of my disability. People read my story and say, ‘You are a role model to me.’ Hearing that from others is what drives me forward.”Ola
World-Class T‑Cell Manufacturing
Flexibility to produce multiple T‑cell and CAR T immunotherapies
Dedicated, expandable ATOM (Atara T‑Cell Operations & Manufacturing) facility in Thousand Oaks, CA
Latest News
May 27, 2020
Atara Biotherapeutics Announces Pricing of $175.5 Million Public Offering
View Press Release View All Press Releases View Press ReleaseMay 26, 2020
Atara Biotherapeutics Announces Proposed Offering of Common Stock and Pre‑Funded Warrants
View Press Release View All Press Releases View Press ReleaseMay 26, 2020
